Work

Abstract 1323: CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients

Year: 2019

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2019-1323

Authors: Hongying Zhang, Andrea Local, Jeffrey W. Tyner, Stephen E. Kurtz, Beth Wilmot, Shannon Mcweeney, Brian J. Druker, Stephen B. Howell, William G. Rice

Institutions: Aptose Biosciences (United States), Oregon Health & Science University, University of California San Diego, Moores Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2954624032

Cites:

Cited by:

Related to: 10